Bristol-Myers Squibb Co: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Bristol-Myers Squibb Co Unternehmen

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Bristol-Myers Squibb Co Informationen



BörsenkürzelBMY

Name des UnternehmensBristol-Myers Squibb Co

IPO-datumMar 17, 1980

CEOBoerner (Christopher S)

Anzahl der mitarbeiter34100

WertpapierartOrdinary Share

GeschäftsjahresendeMar 17

AddresseRoute 206 And Province Line Road

StadtPRINCETON

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl08543

Telefon16092524621

Websitehttps://www.bms.com

BörsenkürzelBMY

IPO-datumMar 17, 1980

CEOBoerner (Christopher S)

Führungskräfte von Bristol-Myers Squibb Co



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer

63.90K

+1182.00%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

19.77K

+3068.00%

Dr. Julia A. Haller, M.D.

Independent Director

13.62K

--

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

12.44K

+5789.00%

Ms. Cari Gallman

Executive Vice President, General Counsel and Chief Policy Officer

11.07K

+2226.00%

Mr. Peter J. (Pete) Arduini

Independent Director

--

Mr. Theodore R. Samuels, II

Lead Independent Director

--

Dr. Karen H. Vousden, Ph.D.

Independent Director

--

Ms. Phyllis R. Yale

Independent Director

--

Mr. David V. Elkins

Executive Vice President, Chief Financial Officer, Member of the Leadership Team

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer

63.90K

+1182.00%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

19.77K

+3068.00%

Dr. Julia A. Haller, M.D.

Independent Director

13.62K

--

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

12.44K

+5789.00%

Ms. Cari Gallman

Executive Vice President, General Counsel and Chief Policy Officer

11.07K

+2226.00%

Mr. Peter J. (Pete) Arduini

Independent Director

--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Eliquis

3.75B

30.65%

Opdivo

2.60B

21.26%

Orencia

964.00M

7.89%

Yervoy

739.00M

6.05%

Other

691.00M

5.65%

Andere

3.48B

28.51%

Nach RegionUSD

Name

Umsatz

Anteil

United States

8.33B

68.15%

International

3.60B

29.47%

other

290.00M

2.37%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Eliquis

3.75B

30.65%

Opdivo

2.60B

21.26%

Orencia

964.00M

7.89%

Yervoy

739.00M

6.05%

Other

691.00M

5.65%

Andere

3.48B

28.51%

Aktionärsstatistik

Aktualisiert: Thu, Jan 29

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

9.71%

BlackRock Institutional Trust Company, N.A.

4.98%

State Street Investment Management (US)

4.74%

Charles Schwab Investment Management, Inc.

3.59%

JP Morgan Asset Management

2.90%

Andere

74.08%

Aktionäre

Anteil

The Vanguard Group, Inc.

9.71%

BlackRock Institutional Trust Company, N.A.

4.98%

State Street Investment Management (US)

4.74%

Charles Schwab Investment Management, Inc.

3.59%

JP Morgan Asset Management

2.90%

Andere

74.08%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

44.78%

Investment Advisor/Hedge Fund

25.99%

Research Firm

2.97%

Pension Fund

2.58%

Hedge Fund

2.50%

Bank and Trust

2.03%

Sovereign Wealth Fund

1.74%

Insurance Company

0.19%

Family Office

0.06%

Andere

17.14%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

3973

1.68B

84.73%

-171.91K

2025Q3

4147

1.68B

85.10%

-5.79M

2025Q2

4212

1.69B

83.90%

+15.56M

2025Q1

4284

1.67B

82.20%

-238.41K

2024Q4

4280

1.64B

80.20%

+45.34M

2024Q3

4106

1.59B

79.76%

+6.69M

2024Q2

4097

1.58B

82.24%

-51.64M

2024Q1

4107

1.64B

80.22%

+12.13M

2023Q4

4104

1.60B

80.80%

-21.68M

2023Q3

4025

1.62B

80.17%

-24.04M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

194.95M

9.58%

+1.00M

+0.52%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

101.38M

4.98%

+2.01M

+2.02%

Sep 30, 2025

State Street Investment Management (US)

96.60M

4.74%

+1.86M

+1.96%

Sep 30, 2025

Charles Schwab Investment Management, Inc.

73.04M

3.59%

+2.24M

+3.16%

Sep 30, 2025

JP Morgan Asset Management

59.07M

2.9%

-8.34M

-12.37%

Sep 30, 2025

Geode Capital Management, L.L.C.

46.55M

2.29%

+377.61K

+0.82%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

33.57M

1.65%

-1.60M

-4.55%

Jun 30, 2025

Capital International Investors

32.39M

1.59%

-33.78M

-51.05%

Sep 30, 2025

Columbia Threadneedle Investments (US)

29.79M

1.46%

+405.79K

+1.38%

Sep 30, 2025

PRIMECAP Management Company

22.09M

1.09%

-850.33K

-3.71%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Fri, Dec 5

Name

Anteil

VanEck Pharmaceutical ETF

9.15%

First Trust NASDAQ Pharmaceuticals ETF

7.58%

Franklin US Dividend Booster Index ETF

5.08%

WBI Power Factor High Dividend ETF

4.88%

VanEck Morningstar Wide Moat Value ETF

4.34%

iShares U.S. Pharmaceuticals ETF

4.31%

Schwab U.S. Dividend Equity ETF

3.74%

ETC 6 Meridian Hedged Equity Index Option ETF

3.68%

ETC 6 Meridian Mega Cap Equity ETF

3.58%

Brookstone Value Stock ETF

3.48%

VanEck Pharmaceutical ETF

Anteil9.15%

First Trust NASDAQ Pharmaceuticals ETF

Anteil7.58%

Franklin US Dividend Booster Index ETF

Anteil5.08%

WBI Power Factor High Dividend ETF

Anteil4.88%

VanEck Morningstar Wide Moat Value ETF

Anteil4.34%

iShares U.S. Pharmaceuticals ETF

Anteil4.31%

Schwab U.S. Dividend Equity ETF

Anteil3.74%

ETC 6 Meridian Hedged Equity Index Option ETF

Anteil3.68%

ETC 6 Meridian Mega Cap Equity ETF

Anteil3.58%

Brookstone Value Stock ETF

Anteil3.48%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 18.64B USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Dec 10, 2025

BMY.NB Interim Cash Dividend of gross USD 0.63 paid on Feb 02, 2026 going ex on Jan 02, 2026 with reinvestment option

Jan 02, 2026

Feb 02, 2026

Jan 02, 2026

Sep 17, 2025

BMY.NB Final Cash Dividend of gross USD 0.62 paid on Nov 03, 2025 going ex on Oct 03, 2025 with reinvestment option

Oct 03, 2025

Nov 03, 2025

Oct 03, 2025

Jun 17, 2025

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Aug 01, 2025 going ex on Jul 03, 2025 with reinvestment option

Jul 03, 2025

Aug 01, 2025

Jul 03, 2025

Mar 03, 2025

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on May 01, 2025 going ex on Apr 04, 2025 with reinvestment option

Apr 04, 2025

May 01, 2025

Apr 04, 2025

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten